SPM-Focused Inflammation Resolution Protocol

EPA and DHA are the direct biosynthetic precursors for E-series resolvins and D-series resolvins, protectins, and maresins respectively [id=20]. Adequate dietary intake raises RBC membrane phospholipid content of these fatty acids, which is measurable as the omega-3 index and serves as a proxy for tissue SPM production capacity [id=23]. Fatty fish (salmon, mackerel, sardines) and algae-derived oils are the principal dietary sources reported in the literature.

Lipoxins (LXA4, LXB4) are the first-described SPMs and are derived from arachidonic acid (AA) via sequential lipoxygenase action [id=20]. They halt neutrophil chemotaxis and stimulate monocyte-mediated clearance, representing an endogenous brake on early inflammation. A diet that does not excessively suppress AA — while also not driving unchecked pro-inflammatory eicosanoid production — may support the lipoxin arm of the resolution programme [id=19].

Resolution initiation depends on the timely class-switch from pro-inflammatory prostaglandins and leukotrienes toward SPMs [id=19]. Diets that chronically over-activate the COX and LOX pathways toward pro-inflammatory outputs may delay this class-switch and impair the resolution programme. The literature describes a Mediterranean-style dietary pattern as consistent with supporting the balance between initiation and resolution phases [id=19, id=20].

The active resolution programme described in the literature — including macrophage efferocytosis and SPM-mediated neutrophil clearance — occurs within a systemic neuroimmune context that is sensitive to circadian disruption [id=19]. Sleep deprivation is associated with sustained pro-inflammatory signalling that may impair the class-switch toward SPM-dominated resolution, as the initiation and resolution phases are temporally regulated [id=19].

Chronic stress activates HPA-axis and sympathoadrenal pathways that sustain pro-inflammatory cytokine and eicosanoid output, prolonging the initiation phase and potentially competing with the lipid mediator class-switch to SPMs [id=19]. The active resolution framework underscores that any factor maintaining pro-inflammatory drive can delay or abort the resolution programme, making stress management a mechanistically-relevant adjunct [id=19].

When dietary intake is insufficient to achieve a target omega-3 index, concentrated EPA and DHA supplements are the principal intervention reported in the literature to increase substrate availability for resolvin, protectin, and maresins biosynthesis [id=20, id=23]. The omega-3 index responds dose-dependently to supplementation and provides a quantitative readout of repletion status [id=23].

Maresins and protectins are both biosynthesised from DHA — maresins via macrophage-specific routes and protectins via LOX-dependent pathways [id=20]. For individuals who do not consume fish, microalgae-derived DHA supplements represent the literature-documented alternative to raise DHA substrate levels and support these resolution mediator families [id=20, id=23].

The resolution phase described by Serhan and colleagues involves active cellular programmes — including neutrophil apoptosis, macrophage polarisation, and efferocytosis — that are influenced by systemic metabolic and inflammatory tone [id=19, id=77]. Regular moderate exercise is reported in the literature to promote macrophage phenotypes consistent with pro-resolving function and to reduce chronic low-grade inflammatory burden that impairs resolution [id=19].

The omega-3 index — EPA + DHA as a percentage of total RBC membrane phospholipid fatty acids — is the standardized, clinically-validated proxy for tissue omega-3 status and, by extension, SPM production capacity [id=23]. A baseline measurement establishes starting substrate status and allows individualized dietary or supplementation targets to be derived from the literature.

RBC turnover takes approximately 90–120 days, meaning meaningful change in the omega-3 index requires 3–4 months of sustained dietary or supplemental intervention [id=23]. Repeat testing allows assessment of whether the SPM precursor substrate pool has reached the range associated with robust resolution physiology in the literature.

Emerging bulk and single-cell RNA sequencing data identify efferocytosis-related genes as diagnostically relevant in atherosclerosis, with immune infiltration patterns linked to resolution competence [id=77]. In clinical research contexts, assessing efferocytotic capacity alongside SPM substrate status may provide a more complete picture of an individual's resolution phenotype, particularly in the setting of cardiovascular disease.

High-dose EPA+DHA supplementation has antiplatelet and mild anticoagulant properties documented in the literature, which may potentiate the effect of anticoagulant or antiplatelet medications [id=23]. Clinicians reviewing this evidence should note that dose escalation into the 3–4 g/day range reported for omega-3 index optimisation warrants assessment of bleeding risk in patients on relevant medications.

Aspirin at low doses acetylates COX-2, triggering production of aspirin-triggered lipoxins and aspirin-triggered resolvins — distinct SPM variants with potent pro-resolving activity [id=20, id=19]. However, non-selective NSAIDs that fully suppress COX may impair prostaglandin-mediated initiation signals that are required to prime the subsequent SPM class-switch, potentially blunting resolution [id=19]. This pharmacological interaction is noted in the resolution literature as clinically relevant.